|
|
Post by suebeeee1 on Feb 10, 2015 10:19:45 GMT -5
MannKind (MNKD) Looks Good: Stock Adds 7.8% in Session - Tale of the Tape
9:25a ET February 10, 2015 (Zacks.com) Print
MannKind Corp. (MNKD) was a big mover last session with its shares rising nearly 8% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has gained roughly 41% since Jan 21.
This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
MannKind currently has a Zacks Rank #3 (Hold) and its Earnings ESP is 0.00%.
|
|
|
|
Post by Chris-C on Feb 10, 2015 14:21:09 GMT -5
The latest Seeking Alpha article on Mannkind from Psycho Analyst: seekingalpha.com/article/2902656-mannkind-investors-dont-screw-up-the-afrezza-launch?page=2&auth_param=ojcm:1adka81:b5b0b1e1128d9e8a4757ab8d5984f6c9&uprof=51I have to say that in my experience as a biotech investor, I have never before been aware of an effort by investors in a legitimate company such as Mannkind to infiltrate the boards of user/consumers/patients to try to hype a product. Perhaps it's just that I wasn't paying attention closely enough, but in my view, this is totally out of line and counterproductive and makes a good product seem illegitimate to the people being "informed" by investors who have a stake in seeing a successful launch. What is it about the American public that gives it such a limited understanding of the important relationship between conflict of interest and credibility? In my opinion, anyone who purchases shares in a company and feels that they need to become part of the sales force should reassess their participation in the market as retail investors. JM2CW. GLTA Chris-C |
|
|
|
Post by cubonwallstreet on Feb 10, 2015 15:11:55 GMT -5
I could not agree more. The people doing this are likely the same people who were extremely impatient and annoyed with Mannkind and Sanofi's silence between partnership and launch. These are likely the same people that moaned and wondered why there have been no commercials, advertisements, press releases, 60 Minutes spots, etc.
To date, both companies have done everything they said they would do and in a very timely manner. Let them do their job.
|
|
|
|
Post by mannmade on Feb 10, 2015 19:50:50 GMT -5
Vaccinogen Elects Hakan Edstrom to Board of Directors FREDERICK, Md., Feb. 10, 2015 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a leading cancer immunotherapy company, announced today that Hakan Edstrom, a healthcare industry veteran with more than 40 years of experience, has been elected to the company's Board of Directors. He will also chair the company's Compensation Committee in this new role and serve on the company's Audit Committee. "This is an extremely exciting time for Vaccinogen. I'm especially looking forward to helping the company advance the development of the OncoVAX® platform and launch the patient-specific vaccine into its first target market, stage II colon cancer," said Mr. Edstrom. "I believe this truly personalized approach in oncology is the key towards providing better treatment for patients. We've learned over the years that cancer is a highly heterogeneous and personalized disease. I believe Vaccinogen is uniquely positioned to address this need through its tumor-cell vaccine approach which teaches the body to attack its own cancer cells and prevent recurrence of late-stage disease." Mr. Edstrom was recently named Chief Executive Officer of MannKind Corporation, following his 14-year tenure as President and Chief Operating Officer of the company. He previously held leadership roles with Bausch & Lomb, serving as Vice President and President of the Global Surgical Division and Senior Corporate Vice President of the America's Region. Prior to these roles, Mr. Edstrom was also Chief Executive Officer of Chiron Vision which was acquired by Bausch & Lomb. He also held various executive positions with Pharmacia Corporation including President and Chief Executive Officer of Pharmacia Ophthalmics, Inc. He has also served as the Director of the Greater Los Angeles Chapter of the Swedish-American Chamber of Commerce. He was a member of the Board of Directors of Biora Inc., Gimbel Vision International, Ixion Inc. and Q-Med AB. Mr. Edstrom was educated in Sweden and holds a Masters in Business Administration from the Stockholm School of Economics. "We are pleased to welcome Mr. Edstrom to the Board of Directors," said Andrew L. Tussing, Vaccinogen's President and Chief Executive Officer. "The vast experience he brings to the Vaccinogen executive leadership team will help accelerate the company's efforts to make OncoVAX® commercially available to millions of patients afflicted with various forms of cancer." Vaccinogen Chairman of the Board, Benjamin S. Carson, Sr., MD, also agreed and added, "We are thrilled to have Mr. Edstrom join our stellar team. His proven leadership record in the pharmaceutical industry and decades of experience building and sustaining innovative companies will play a critical part of our company's success as we work to provide a first-in-class immunotherapy for the prevention of cancer recurrence." About Vaccinogen, Inc. Vaccinogen, Inc. is a cancer vaccine company that is clinically testing OncoVAX®, a treatment designed to prevent the recurrence of colon cancer and potentially other solid tumors. It is a patented process that leverages a patient's own live tumor cells to launch a broad immune response against minimal residual disease. The Company believes that OncoVAX®, at an optimal dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in preventing cancer recurrence after surgical resection by addressing the diversity of cancer cells inherent to each patient's tumor. Five clinical studies of OncoVAX®, including a Phase III trial with the optimum dose and regimen, have been completed to date. The Company expects to begin enrolling patients in a pivotal Phase IIIb trial under an FDA Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) within sixty (60) days of obtaining adequate funding. More information is available at www.vaccinogeninc.com. Forward Looking Statement Some of the statements contained in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "believe", "plan", "intend", "expect", "likely", "may", "should", "will", and similar references to future periods. Vaccinogen has based these forward-looking statements largely on its expectations and projections about future events and financial trends affecting the financial condition and/or operating results of our business. Forward-looking statements involve risks and uncertainties; particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. In addition, these forward-looking statements involve risks and uncertainties outlined in our most recent periodic reports filed with the Securities and Exchange Commission. There are important factors that could cause actual results to be substantially different from the results expressed or implied by these forward-looking statements. Therefore, you should not rely on these forward-looking statements. Vaccinogen does not undertake any obligation to update this forward-looking information. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vaccinogen-elects-hakan-edstrom-to-board-of-directors-300033504.html SOURCE Vaccinogen, Inc. |
|
|
|
Post by mnkdorbust on Feb 10, 2015 22:06:42 GMT -5
|
|
|
|
Post by babaoriley on Feb 10, 2015 23:58:02 GMT -5
Vaccinogen, Inc - so that's what Diane Palumbo is doing with her sales proceeds!
|
|
|
|
Post by Chris-C on Feb 11, 2015 0:11:18 GMT -5
Vaccinogen, Inc - so that's what Diane Palumbo is doing with her sales proceeds! Palumbo - the woman who never saw an option award that she didn't want to turn into immediate cash. Scientists have shown that some people (apparently, her included) have heritable tendencies that limit their ability to delay gratification. In this case, the tendency interferes with her ability to wait for a share of the company's stock to appreciate in value, regardless of how her sale transactions may appear when revealed to the investment community or how they may affect shareholders (including Mr. Mann) whose hard earned cash has allowed her to retain her benefit laden job with its generous compensation. just sayin'... Chris-C |
|
|
|
Post by suebeeee1 on Feb 11, 2015 2:14:49 GMT -5
topics.nytimes.com/top/news/science/topics/atomic_weapons/index.html?inline=nyt-classifierAbout Vaccinogen, Inc. The Company believes that OncoVAX®, at an optimal dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in preventing cancer recurrence after surgical resection by addressing the diversity of cancer cells inherent to each patient's tumor. Five clinical studies of OncoVAX®, including a Phase III trial with the optimum dose and regimen, have been completed to date. Does anyone else suspect that OncoVAXs vaccine may be delivered via Technosphere?. More information at our next conference call perhaps? |
|
|
|
Post by liane on Feb 11, 2015 5:41:47 GMT -5
I just noticed the name of the Vaccinogen Chairman of the Board, Benjamin Carson - whom I often follow for his healthcare views: en.wikipedia.org/wiki/Ben_Carson |
|
|
|
Post by noonen on Feb 11, 2015 5:53:35 GMT -5
Interesting for sure. but does it have "the graph" of Afrezza? fast in fast out? also, for anyone that knows, how big of a deal is the below statement? is it a huge benefit if insulin goes through the liver, or just a small incremental benefit? 'The beauty of this pill is that it mimics the natural production of insulin by delivering insulin to the liver,' says Dr Kidron. 'If you inject insulin, it goes straight into the bloodstream, bypassing the liver which also needs insulin. An oral insulin would obviously be welcome and if it works be a big deal. It would best be a long acting type of insulin even if taken multiple times a day. As ever the devil is in the detail though... Emisphere is not at their first drug but haven't been very 'lucky' so far. I briefly invested in them (and made a small profit) for their calcitonin drug which never worked (it seas a delivery problem though). I have't followed them in years by tackling insulin they are going after something much more complex and 'fidgety' then calcitonin. Edit: from Emispheres website: Emisphere has partnered with Novo Nordisk to develop and commercialize the oral delivery of their insulin compounds. The project is currently in the pre-clinical stage. That is a long way from being '3 years out'... Don't know anything about the partnership, revenue split etc. Strangely the market cap seems to be about 24 million $? Weird... indeed. i definitely get both that if an oral works out it's a very good thing and that it's not an immediate threat. definitely not trying to make a big issue, or really any issue out of this. just curious about that liver comment. I know nothing about the liver and insulin, and the interwebs articles were way over my head that I found. Comprehension went to zero quickly when I got to this line: "The major glucose transporter in the muscle, adipose and other target tissues is the GLUT4 transporter. When insulin binds to the insulin receptors on the surface of target cells, it stimulates translocation of GLUT4 transporters from storage vesicles to the plasma membrane." There are at least 5 words there I had to google. The article also used the word hepatocytes. whhhhat? So to dumb it down (for me), scale of 1 to 100. we're talking insulin "goodness". going through the liver is 100. what is straight to the bloodstream? 10? 50? 98? 79.21456? kidding. is that not even a fair comparison bc of all the other things happening in the system? Is it a small enough improvement that it could be easily outweighed by Afrezza's super fast entry/exit? (in 10 years when this oral it gets to market?) |
|
|
|
Post by savzak on Feb 11, 2015 6:27:12 GMT -5
I just noticed the name of the Vaccinogen Chairman of the Board, Benjamin Carson - whom I often follow for his healthcare views: en.wikipedia.org/wiki/Ben_CarsonGenerally speaking, I often find Dr. Carson's healthcare views in accord with my own. |
|
|
|
Post by 4allthemarbles on Feb 11, 2015 9:18:24 GMT -5
I just noticed the name of the Vaccinogen Chairman of the Board, Benjamin Carson - whom I often follow for his healthcare views: en.wikipedia.org/wiki/Ben_CarsonGenerally speaking, I often find Dr. Carson's healthcare views in accord with my own. Clever.... I also find his healthcare views match my some of my views. I can tell you he is a super intelligent man- they don't let anyone become neurosurgeons. Except on the Internet. |
|
|
|
Post by joeypotsandpans on Feb 11, 2015 11:05:15 GMT -5
|
|
|
|
Post by jpg on Feb 11, 2015 11:43:21 GMT -5
An oral insulin would obviously be welcome and if it works be a big deal. It would best be a long acting type of insulin even if taken multiple times a day. As ever the devil is in the detail though... Emisphere is not at their first drug but haven't been very 'lucky' so far. I briefly invested in them (and made a small profit) for their calcitonin drug which never worked (it seas a delivery problem though). I have't followed them in years by tackling insulin they are going after something much more complex and 'fidgety' then calcitonin. Edit: from Emispheres website: Emisphere has partnered with Novo Nordisk to develop and commercialize the oral delivery of their insulin compounds. The project is currently in the pre-clinical stage. That is a long way from being '3 years out'... Don't know anything about the partnership, revenue split etc. Strangely the market cap seems to be about 24 million $? Weird... indeed. i definitely get both that if an oral works out it's a very good thing and that it's not an immediate threat. definitely not trying to make a big issue, or really any issue out of this. just curious about that liver comment. I know nothing about the liver and insulin, and the interwebs articles were way over my head that I found. Comprehension went to zero quickly when I got to this line: "The major glucose transporter in the muscle, adipose and other target tissues is the GLUT4 transporter. When insulin binds to the insulin receptors on the surface of target cells, it stimulates translocation of GLUT4 transporters from storage vesicles to the plasma membrane." There are at least 5 words there I had to google. The article also used the word hepatocytes. whhhhat? So to dumb it down (for me), scale of 1 to 100. we're talking insulin "goodness". going through the liver is 100. what is straight to the bloodstream? 10? 50? 98? 79.21456? kidding. is that not even a fair comparison bc of all the other things happening in the system? Is it a small enough improvement that it could be easily outweighed by Afrezza's super fast entry/exit? (in 10 years when this oral it gets to market?) The first pass into the liver vs systemic then into the liver are more context specific the. Anything else. A slow drip into the liver from the portal system (a PO route) doesn't offer a physiological peak effect as the pancreas (and Afrezza) do so different concepts might be mixed together to favorably spin whatever point of view needs emphasis? In this case oral insulin... And I so wouldn't worry about this for the foreseeable future. |
|
|
|
Post by noonen on Feb 11, 2015 13:52:36 GMT -5
indeed. i definitely get both that if an oral works out it's a very good thing and that it's not an immediate threat. definitely not trying to make a big issue, or really any issue out of this. just curious about that liver comment. I know nothing about the liver and insulin, and the interwebs articles were way over my head that I found. Comprehension went to zero quickly when I got to this line: "The major glucose transporter in the muscle, adipose and other target tissues is the GLUT4 transporter. When insulin binds to the insulin receptors on the surface of target cells, it stimulates translocation of GLUT4 transporters from storage vesicles to the plasma membrane." There are at least 5 words there I had to google. The article also used the word hepatocytes. whhhhat? So to dumb it down (for me), scale of 1 to 100. we're talking insulin "goodness". going through the liver is 100. what is straight to the bloodstream? 10? 50? 98? 79.21456? kidding. is that not even a fair comparison bc of all the other things happening in the system? Is it a small enough improvement that it could be easily outweighed by Afrezza's super fast entry/exit? (in 10 years when this oral it gets to market?) The first pass into the liver vs systemic then into the liver are more context specific the. Anything else. A slow drip into the liver from the portal system (a PO route) doesn't offer a physiological peak effect as the pancreas (and Afrezza) do so different concepts might be mixed together to favorably spin whatever point of view needs emphasis? In this case oral insulin... And I so wouldn't worry about this for the foreseeable future. jpg, thanks for the explanation there, very helpful. now it's back to the shorts and their ridiculous borrow rates and attacks. looks like they got some horses in there today.. |
|
